NEW HAVEN, Conn., June 12, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), today reminded its shareholders to vote on proposals 1-6 in
accordance with the recommendations of the Board, as set out in the proxy material previously mailed to the shareholders on or
about June 5, 2018, for the Company's upcoming Annual General Meeting which will be held at the Company’s office in New Haven on June 15
2018 at 9:30 Eastern Time:
The Annual Meeting is a few days away; hence we request that you vote your shares by proxy following the methods as instructed
by the notice:
VOTE BY INTERNET - www.proxyvote.com
Use the Internet to transmit your voting instructions and for electronic delivery of information. Please Vote by 11:59 p.m. Eastern
Time on June 14, 2018. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records
and to create an electronic voting instruction form.
VOTE BY PHONE - 1-800-690-6903
Use any touch-tone telephone to transmit your voting instructions. Please Vote by 11:59 p.m. Eastern Time on June 14, 2018. Have
your proxy card in hand when you call and then follow the instructions.
Your Participation is Important — Please Vote Today!
“As we approach the completion of a year since the merger, we have turned around the business and are starting to see positive
momentum,” commented Ilan Danieli, CEO of Precipio. “The measures management is seeking shareholder approval on are critical to the
continued growth and success of the company. I hope to see strong support from our shareholders.”
If you have any questions concerning the 2018 Annual Meeting and you are the stockholder of record of your
shares, please contact Precipio’s CEO Ilan Danieli at (203) 787 7888 ex. 536. If your shares are held by a broker or other nominee
(that is, in “street name”), please contact your broker or other nominee for questions concerning the 2018 Annual Meeting. If you
have already voted, you do not need to do anything further and we thank you for your support.
About Precipio
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect,
expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and
their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research,
diagnostics and treatment, initially the Yale School of Medicine, Precipio offers a new standard of diagnostic accuracy enabling
the highest level of patient care. For more information, please visit www.precipiodx.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements,” within the meaning of federal securities laws,
including statements related to ICP technology, including other financial projections and potential market opportunity, plans and
prospects and other statements containing the words “anticipate,” “intend,” “may,” “plan,” “predict,” “will,” “would,” “could,”
“should,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation
Reform Act of 1995. The Company's actual results could differ materially from those anticipated in these forward-looking statements
as a result of various factors. Factors that could cause future results to materially differ from the recent results or those
projected in forward-looking statements include the known risks, uncertainties and other factors described in the Company’s
quarterly report on form 10-Q for the quarter ended March 31, 2018 and on the Annual Report on Form 10-K for the year ended
December 31, 2017, the Company’s prior filings and from time to time in the Company’s subsequent filings with the Securities and
Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to
differ materially from those referred to in such statements. All information in this press release is as of the date of the release
and the Company does not undertake any duty to update this information, including any forward-looking statements, unless required
by law.
Additional Information and where to find it
The Company has filed a definitive proxy statement and associated proxy card with the U.S. Securities and
Exchange Commission (the “SEC”) in connection with the solicitation of proxies for the Annual Meeting of Shareholders of the
Company (the “Annual Meeting”) on May 29, 2018. The Company, its directors, its executive officers and certain other individuals
set forth in the definitive proxy statement will be deemed participants in the solicitation of proxies from shareholders in respect
of the Annual Meeting. Information regarding the names of the Company’s directors and executive officers and certain other
individuals and their respective interests in the Company by security holdings or otherwise is set forth in the Company’s quarterly
report on form 10-Q for the quarter ended March 31, 2018 and on the Annual Report on Form 10-K for the year ended December 31,
2017, has been included in the definitive proxy statement filed with the SEC on May 29, 2019. Details containing the nominees of
the Company’s Board of Directors for election at the 2018 Annual Meeting of Shareholders are included in the definitive proxy
statement. BEFORE MAKING ANY VOTING DECISION, SHAREHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR
FURNISHED TO THE SEC, INCLUDING THE DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO AND ACCOMPANYING PROXY CARD, BECAUSE
THEY CONTAIN IMPORTANT INFORMATION. The Company’s definitive proxy statement and a form of proxy have been mailed to shareholders
of the Company. Investors and shareholders can obtain a copy of the documents filed by the Company with the SEC, including the
definitive proxy statement, free of charge by visiting the SEC’s website, www.sec.gov. The Company’s shareholders can also obtain,
without charge, a copy of the definitive proxy statement and other relevant filed documents when available from the Company’s
website at www.precipiodx.com.
Inquiries: investors@precipiodx.com +1-203-787-7888
